Further studies are needed to clarify whether ZIKV treatment improves functional antitumor CD8+ T cell responses against GSCs or common glioma antigens by promoting antigen cross-presentation or other immunomodulatory mechanisms. Here, CD8A is linked to central nervous system cancer.